Medindia
Medindia LOGIN REGISTER
Advertisement

Assay Designs(TM), Inc. and the Spinal Muscular Atrophy Foundation Announce Collaboration To Accelerate the Discovery of New Therapeutics for Spinal Muscular Atrophy (SMA)

Tuesday, September 16, 2008 General News
Advertisement
ANN ARBOR, Mich., Sept. 15 Assay Designs and the SpinalMuscular Atrophy Foundation (SMAF) are very pleased to announce acollaborative agreement for development of reagents and assays for SMN(Survival Motor Neuron) protein to expedite drug discovery and developmentefforts for spinal muscular atrophy (SMA), the leading genetic cause ofmortality in infants and toddlers. "Assay Designs is excited and proud to havebeen selected by the SMA Foundation, and to help enable better understandingand ultimately improved treatment for this debilitating illness," commentedDan Calvo, President and CEO of Assay Designs. Providing a reliable andwidely-available ELISA kit for measuring SMN protein levels will greatlysimplify and accelerate the process of assessing the efficacy of potentialdrugs in clinical trials, which is key to the successful development of newtherapeutics for this devastating disease. "We are pleased to bring resultsfrom the research sector out for general use in the community," states LorenEng, president of the SMA Foundation.
Advertisement

SMA is a genetic, motor neuron disease characterized by the wasting ofskeletal muscles. Caused by progressive degeneration of nerve cells in thespinal cord, the disease leads to increasing muscular weakness and atrophy.It is estimated that approximately 1 in 6,000 to 1 in 10,000 infants are bornannually worldwide with SMA. SMA is often compared to polio because the samespinal cord cells are attacked in each disease. Over time, patients afflictedby this disease continue to lose muscle control and strength, progressivelyleading to inability to walk, stand, sit up and breathe.
Advertisement

Founded in 2003, the Spinal Muscular Atrophy Foundation is a nonprofitorganization dedicated to accelerating progress towards a treatment and curefor spinal muscular atrophy through targeted funding of clinical research andnovel drug development efforts. Since its inception, the Foundation hasawarded over $50 million in sponsored research agreements. In addition, theFoundation is committed to raising awareness and generating support forincreased research efforts in SMA among the leaders of industry andgovernment.

For more than 16 years Assay Designs has supplied the worldwide biomedicalresearch community with immunoanalytical assay solutions for the precisequantification of biomarkers in a variety of sample matrices and species.Since 2005 ADI also provides the full spectrum of Stressgen(R) immunologicalreagents such as antibodies and proteins, to aid drug discovery and basicresearch. Assay Designs offers customers one-stop-shop custom developmentservices from antibody and recombinant protein production to the development,validation, and manufacturing of biomarker assays, providing a seamlesstransition and scale up from pre-clinical to clinical applications.

The collaboration with SMAF is in alignment with Assay Designs' mission toprovide researchers with high quality reagents and assays to expedite theirefforts in developing new cures and improving the quality of life forpatients.

About Assay Designs, Inc.

Based in Ann Arbor, MI, Assay Designs develops and manufacturesimmunoassay (ELISA) kits, luminescent reagents, antibodies, proteins, andextracts used for life sciences research. The company markets these productsunder the "Assay Designs" and "Stressgen" brand names. Researchers use thecompany's products to detect and quantify molecules that are important ininflammation, cell signaling, and cellular stress.

SOURCE Assay Designs, Inc.
Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close